Test your lungs know your numbers
  National Lung Health Education Program   Home | Return to Resources page

Prevent Emphysema Now!

Information for Physicians on the Diagnosis and Treatment of COPD

Making the Diagnosis of COPD
How to Test for Emphysema
Who Should Be Treated
Suggested Treatment Emphysema
Other Therapy for Emphysema
Appendix A
Pulmonary Function Reimbursement (as of 6/03)


Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-1505.

Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE Trial. BMJ 2000;320:1297-1303.

Dale LC, Ebbert JO, Hays JT, Hurt RD: Treatment of nicotine dependence. Mayo Clinic Proc 2000;75:1311-1316.

Ferguson GT, Enright PL, Buist AS, Higgins MW: Office spirometry for lung health assessment in adults. A consensus statement from the National Lung Health Education Program. Chest 2000;117:1146-1161.

Guyatt GH, Townsend M, Nogradi S, et al: Acute response to bronchodilator — an imperfect guide for bronchodilator therapy. Arch Intern Med 1988;148:1949-1952.

Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-187.

Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al: A comparison of sustained-released bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-1202.

Jorenby DE, Lieschow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al: A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-691.
Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. New Engl J Med 2000;343:1902-1909.

Mannino DM, Gagnon RC, Petty TL, Lydick E: Obstructive lung disease and low lung function in adults in the United States. Arch Intern Med 2000;160:1683-1689.

Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al: Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999;340:1941-1947.

Peto R, Speizer FE, Cochrane AL, Moore F, Fletcher CM, Tinker CM, et al: The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983;128:491500.

Soriano JB, Vestbo J, Pride NB, et al: Sirvival in COPD patients after regular use of fluticasone propionate and salmuterol in general practice. Evidence of improved survival in COPD patients with the regular use of both agents. Eur Respir J 2002; 20:819-825.

Swanney MP, Jensen RL, Crichton DA, Beckert LE, Cardno LA, Crapo RO: FEV6 is an acceptable surrogate for FVC in the spirometric diagnosis
of airway obstruction and restriction. Am J Respir Crit Care Med 2000;162:917-919.

Vinken W, et al: Improved health outcomes in patients with COPD during one year’s treatment with tiotropium. Eur Respir J 2002;19:209-216.